Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Get Free Report) was downgraded by analysts at BTIG Research from a "strong-buy" rating to a "hold" rating in a report issued on Thursday, Marketbeat.com reports.
VRNA has been the subject of several other research reports. Cowen began coverage on shares of Verona Pharma PLC American Depositary Share in a research report on Monday, April 28th. They set a "buy" rating for the company. HC Wainwright upped their price target on shares of Verona Pharma PLC American Depositary Share from $85.00 to $90.00 and gave the stock a "buy" rating in a research report on Monday, June 2nd. Piper Sandler set a $160.00 price target on shares of Verona Pharma PLC American Depositary Share and gave the stock an "overweight" rating in a research report on Monday, June 23rd. Roth Capital reaffirmed a "buy" rating and issued a $116.00 price objective (up previously from $92.00) on shares of Verona Pharma PLC American Depositary Share in a report on Wednesday, June 18th. Finally, Canaccord Genuity Group downgraded shares of Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating and set a $107.00 price objective for the company. in a report on Wednesday. Nine equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $107.45.
View Our Latest Stock Report on Verona Pharma PLC American Depositary Share
Verona Pharma PLC American Depositary Share Stock Performance
Shares of Verona Pharma PLC American Depositary Share stock traded down $0.02 during trading on Thursday, hitting $104.83. 10,916,452 shares of the stock were exchanged, compared to its average volume of 1,598,487. The stock's fifty day moving average is $83.89 and its 200 day moving average is $67.67. The stock has a market cap of $8.92 billion, a PE ratio of -52.42 and a beta of 0.24. The company has a debt-to-equity ratio of 1.07, a quick ratio of 8.73 and a current ratio of 8.86. Verona Pharma PLC American Depositary Share has a 12 month low of $18.51 and a 12 month high of $104.99.
Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The company reported $0.27 EPS for the quarter, topping the consensus estimate of ($0.22) by $0.49. The firm had revenue of $98.65 million for the quarter, compared to the consensus estimate of $41.47 million. As a group, sell-side analysts anticipate that Verona Pharma PLC American Depositary Share will post -1.95 EPS for the current year.
Insider Buying and Selling at Verona Pharma PLC American Depositary Share
In other Verona Pharma PLC American Depositary Share news, CFO Mark W. Hahn sold 400,000 shares of the company's stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $11.40, for a total value of $4,560,000.00. Following the completion of the sale, the chief financial officer directly owned 12,278,992 shares of the company's stock, valued at approximately $139,980,508.80. This represents a 3.15% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, General Counsel Andrew Fisher sold 80,000 shares of the company's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $11.53, for a total transaction of $922,400.00. Following the completion of the sale, the general counsel directly owned 359,999 shares of the company's stock, valued at $4,150,788.47. The trade was a 18.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,965,800 shares of company stock valued at $20,056,881 over the last 90 days. Insiders own 4.80% of the company's stock.
Institutional Investors Weigh In On Verona Pharma PLC American Depositary Share
Institutional investors and hedge funds have recently bought and sold shares of the business. NBC Securities Inc. acquired a new stake in Verona Pharma PLC American Depositary Share during the 1st quarter worth about $34,000. Geneos Wealth Management Inc. raised its holdings in Verona Pharma PLC American Depositary Share by 44.2% during the 1st quarter. Geneos Wealth Management Inc. now owns 630 shares of the company's stock worth $40,000 after buying an additional 193 shares during the period. Acadian Asset Management LLC acquired a new stake in Verona Pharma PLC American Depositary Share during the 1st quarter worth about $48,000. NewEdge Advisors LLC acquired a new stake in Verona Pharma PLC American Depositary Share during the 1st quarter worth about $58,000. Finally, Vermillion Wealth Management Inc. acquired a new stake in Verona Pharma PLC American Depositary Share during the 4th quarter worth about $46,000. 85.88% of the stock is owned by institutional investors and hedge funds.
Verona Pharma PLC American Depositary Share Company Profile
(
Get Free Report)
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.
Featured Articles

Before you consider Verona Pharma PLC American Depositary Share, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Verona Pharma PLC American Depositary Share wasn't on the list.
While Verona Pharma PLC American Depositary Share currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.